Document is current
Any future updates will be listed below
-
Authors
McManus, Hannah D.
Dorff, Tanya https://orcid.org/0000-0001-5990-298X
Morgans, Alicia K. https://orcid.org/0000-0002-6563-4587
Sartor, Oliver
Shore, Neal
Armstrong, Andrew J. https://orcid.org/0000-0001-7012-1754
-
Funding
Funding for this research was provided by:
Novartis Pharmaceuticals Corporation (N/A, N/A, N/A, N/A, N/A, N/A)
- License Information
-
More Information
Article History
Received: 21 June 2024
Revised: 18 September 2024
Accepted: 3 October 2024
First Online: 17 October 2024
Competing interests
: HDM has no conflicts of interest to disclose. TD has received writing support from Pfizer, and has personal consulting or advising relationships with AstraZeneca, Bayer, Janssen Pharmaceuticals, and Sanofi. AM has a consulting relationship with Astellas, AstraZeneca, Bayer, Janssen Pharmaceuticals, Exelixis, Myovant, Merck, Novartis, Pfizer, Telix, and Sanofi. Research collaborations and/or support was received from Astellas, Bayer, Myovant, Pfizer, and Sanofi. OS has received grants or contracts from Advanced Accelerator Applications, Amgen, AstraZeneca, Bayer, Constellation, Endocyte, Invitae, Janssen Pharmaceuticals, Lantheus, Merck, Progenics Pharmaceuticals Inc., and Teneobio; has received consulting fees from Advanced Accelerator Applications, Astellas, AstraZeneca, Bayer, Blue Earth Diagnostics, Bavarian Nordic, Bristol Myers Squibb, Clarity Pharmaceuticals, Clovis, Constellation, Dendreon, EMD Serono, Fusion, Isotopen Technologien Meunchen, Janssen Pharmaceuticals, Myovant, Myriad, Noria Therapeutics, Novartis, Noxopharm, Progenics Pharmaceuticals, Inc., POINT Biopharma Global Inc., Pfizer, Sanofi, Teneobio, Telix, and Theragnostics; has participated on data safety monitoring boards or advisory boards for AstraZeneca, Janssen Pharmaceuticals, Pfizer, and Myovant; and holds stock or stock options in Clarity Pharmaceuticals, Noria Therapeutics, Eli Lilly, Clovis, GlaxoSmithKline, AbbVie, Cardinal Health, and United Health Group. NS has personal consulting or advising relationships with Astellas, Dendreon, Janssen Pharmaceuticals, Bayer, Myriad, MDxHealth, Tolmar, Molvant, Pfizer, AstraZeneca, Merck, Genentech, Pfizer, Urogen, Guardant, Myovant, AbbVie, Amgen, Bristol Myers Squibb, Boston Scientific, Clovis Oncology, Exact Imaging, FerGene, Foundation Medicine, GConcology, Invitae, Nymox, Propella, Sanofi Genzyme, Sesen Bio, Exact Sciences, Pacific Edge, Cold Genesys, Genesis Care, Alessa, Akido, Arquer, Asleris, Clarity, Clovis, Ferring, ImmunityBio, Incyte, Lantheus, Eli Lilly, Minomic, NGM, Nonagen, Novartis, Pacific Edge, Photocure, PlatformQ, Profound, Promaxo, Protara, Speciality Networks, Telix, Vaxllon, Vessi, FIZe Medical, Accord, ANTeV, Bioprotect, Aura Biosciences, CG Oncology, Palette Life, and PREVIEW; and holds a leadership position with Alessa and Photocure. AJA received research support (to Duke) from Astellas, Pfizer, Bayer, Janssen Pharmaceuticals, Dendreon, BMS, AstraZeneca, Merck, Forma, Celgene, Amgen, and Novartis; and has personal consulting or advising relationships with Astellas, Epic Sciences, Pfizer, Bayer, Janssen Pharmaceuticals, Dendreon, BMS, AstraZeneca, Merck, Forma, Celgene, Clovis, Exact Sciences, Myovant, Exelixis, GoodRx, and Novartis.
